HLA antigens in patients with interferon-α-induced autoimmune thyroid disorders in chronic hepatitis C

被引：53

作者：

Kakizaki, S ^{[1
]}

Takagi, H ^{[1
]}

Murakami, E ^{[1
]}

Takayama, H ^{[1
]}

Mori, M ^{[1
]}

机构：

[1] Gunma Univ, Sch Med, Dept Internal Med 1, Maebashi, Gumma 3718511, Japan

来源：

JOURNAL OF HEPATOLOGY | 1999年 / 30卷 / 05期

关键词：

autoimmune thyroid disorders; hepatitis C; HLA; interferon-alpha;

D O I：

10.1016/S0168-8278(99)80131-7

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Background/Aims: To determine the immunological predisposition to autoimmune thyroid disorders induced by interferon-alpha therapy, human leukocyte antigen (HLA) was analyzed in patients with chronic hepatitis C who developed autoimmune thyroid disorders during or after treatment with interferon-alpha. Methods: Four hundred and thirty-nine patients with chronic hepatitis C (278 males and 161 females, aged 20-73 years) were treated with interferon-alpha (natural-alpha, 169; alpha-2a, 82; alpha-2b, 188) for 24 weeks. Results: Seventeen of 439 (3.9%) patients developed symptomatic autoimmune thyroid disorders; these included nine cases of hyperthyroidism and eight cases of hypothyroidism, The incidence of HLA-A2, B46 and Cw7 increased in patients with interferon-alpha-induced autoimmune thyroid disorders. Especially, the incidence of HLA-A2 (15/17; 88.2%) was significantly higher than that observed in the general population in Japan (corrected p-value (p(c)): p(c)<0,003), The odds ratios for the relative risk of the autoimmune thyroid disorders were A2, 10.6 [95% confidence interval, 2.4-46.5]; B46, 4.8 [1.6-14.0]; and Cw7, 3.0 [1,1-7,91, Conclusions: Our study revealed that HLA-AZ is highly linked to the autoimmune thyroid disorders induced by interferon-alpha-therapy in patients with chronic hepatitis C.

引用

页码：794 / 800

页数：7

共 25 条

[1]

Bacq Y, 1996, GASTROEN CLIN BIOL, V20, P303

[2] REVERSIBILITY OF THYROID-DYSFUNCTION INDUCED BY RECOMBINANT ALPHA-INTERFERON IN CHRONIC HEPATITIS-C [J].

BAUDIN, E ;

MARCELLIN, P ;

POUTEAU, M ;

COLASLINHART, N ;

LEFLOCH, JP ;

LEMMONIER, C ;

BENHAMOU, JP ;

BOK, B .

CLINICAL ENDOCRINOLOGY, 1993, 39 (06) :657-661

[3]

CONLON KC, 1990, CANCER, V65, P2237, DOI 10.1002/1097-0142(19900515)65:10<2237::AID-CNCR2820651013>3.0.CO

[4]

2-5

[5]

CZAJA AJ, 1996, J HEPATOL, V24, P663

[6] GRAVES-DISEASE - IMMUNOLOGICAL AND IMMUNOGENETIC INDICATORS OF RELAPSE [J].

DEBRUIN, TWA ;

BOLK, JH ;

BUSSEMAKER, JK ;

STIJNEN, T ;

SCHREUDER, GMT ;

DEVRIES, RRP ;

VANDERHEIDE, D .

BRITISH MEDICAL JOURNAL, 1988, 296 (6632) :1292-1295

[7] Thyroid abnormalities in chronic viral hepatitis and their relationship to interferon alfa therapy [J].

Deutsch, M ;

Dourakis, S ;

Manesis, EK ;

Gioustozi, A ;

Hess, G ;

Horsch, A ;

Hadziyannis, S .

HEPATOLOGY, 1997, 26 (01) :206-210

[8] HLA-A AND DPB1 LOCI CONFER SUSCEPTIBILITY TO GRAVES-DISEASE [J].

DONG, RP ;

KIMURA, A ;

OKUBO, R ;

SHINAGAWA, H ;

TAMAI, H ;

NISHIMURA, Y ;

SASAZUKI, T .

HUMAN IMMUNOLOGY, 1992, 35 (03) :165-172

[9] Side effects of alpha interferon in chronic hepatitis C [J].

Dusheiko, G .

HEPATOLOGY, 1997, 26 (03) :S112-S121

[10] GENE-FREQUENCIES AND HAPLOTYPIC ASSOCIATIONS WITHIN THE HLA REGION IN 916 UNRELATED JAPANESE INDIVIDUALS [J].

HASHIMOTO, M ;

KINOSHITA, T ;

YAMASAKI, M ;

TANAKA, H ;

IMANISHI, T ;

IHARA, H ;

ICHIKAWA, Y ;

FUKUNISHI, T .

TISSUE ANTIGENS, 1994, 44 (03) :166-173

← 1 2 3 →